LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

Search

Karyopharm Therapeutics Inc

Deschisă

SectorSănătate

8.75 -2.45

Rezumat

Modificarea prețului

24h

Curent

Minim

8.55

Maxim

9.88

Indicatori cheie

By Trading Economics

Venit

4.1M

-33M

Vânzări

6.1M

44M

EPS

-3.82

Marjă de profit

-75.213

Angajați

279

EBITDA

1.8M

-23M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+164.18% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

13M

116M

Deschiderea anterioară

11.2

Închiderea anterioară

8.75

Sentimentul știrilor

By Acuity

57%

43%

293 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Karyopharm Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 feb. 2026, 23:57 UTC

Acțiuni populare

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb. 2026, 23:35 UTC

Câștiguri
Principalele dinamici ale pieței

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb. 2026, 23:28 UTC

Câștiguri

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb. 2026, 21:47 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb. 2026, 23:33 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb. 2026, 22:55 UTC

Câștiguri
Acțiuni populare

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb. 2026, 22:23 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb. 2026, 21:57 UTC

Câștiguri

XP 4Q Rev BRL4.95B >XP

12 feb. 2026, 21:52 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 feb. 2026, 21:47 UTC

Câștiguri

Morningstar 4Q Rev $641M >MORN

12 feb. 2026, 21:39 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:38 UTC

Câștiguri

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparație

Modificare preț

Karyopharm Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

164.18% sus

Prognoză pe 12 luni

Medie 16.67 USD  164.18%

Maxim 23 USD

Minim 12 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKaryopharm Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.9501 / 7.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

293 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

help-icon Live chat